Journal of clinical pharmacologyJul 30, 2026

First Human Study of a Long-Lasting GLP-1 Drug in Overweight or Obese Adults Without Type 2 Diabetes

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗OA ↗

Updated Aug 3, 2026

Abstract

The half-life of TE-8105 was about 120 hours.

No accumulation was observed after flat dosing of TE-8105.
Mean accumulation ratios for peak concentration (Cmax) and total exposure (AUC) were 3.75 and 3.00, respectively, after titration dosing.
A mean weight loss of 2.06% was noted from baseline to the end of the study visit with titration dosing.
Four out of eight participants (50%) maintained a weight loss of at least 5%.
Treatment-related adverse effects included nausea (16.7% in Part A, 21.4% in Part B), abdominal pain (4.2%), constipation (4.2% in Part A, 7.1% in Part B), and vomiting (4.2% in Part A, 7.1% in Part B).
TE-8105 was considered safe and well tolerated, suggesting potential for less frequent subcutaneous dosing compared to existing GLP-1 receptor agonists.

Simplified

Glucagon-like peptide-1 (GLP-1) receptor agonists have revolutionized weight management and are becoming essential for the treatment of obesity-related medical conditions. This study aimed to determine the pharmacokinetics, preliminary pharmacodynamics, safety, and tolerability of a long-acting GLP-1 receptor agonist, TE-8105, in overweight or obese adults without T2DM. An open-label study of four single ascending dose cohorts (A1-A4, 0.5, 0.75, 1.5, and 3.0 mg TE-8105, respectively) and two multiple dose cohorts (B1 flat dosing, 1.0 mg TE-8105 Q2W SC for 5 doses, and B2 titration dosing, sequence 2 × 1.5, 2 × 2.0, 2 × 2.5, and 3 × 3.0 mg Q2W SC) was conducted using a combination of in-patient and out-patient assessments. The half-life of TE-8105 was about 120 h. There was no accumulation after flat dosing, but mean (SD) accumulation ratios were 3.75 (0.86) for C_max and 3.00 (0.65) for AUC following titration dosing. The mean % decrease in body weight from baseline to the end of study visit for titration dosing was 2.06%, with 4/8 participants maintaining weight loss of ≥5%. Treatment-related treatment emergent adverse effects (TEAEs) were consistent with the mechanism of action of TE-8105 and dose-dependent, including nausea (Part A: 16.7%; Part B: 21.4%), abdominal pain (Part A: 4.2%), constipation (Part A: 4.2%; Part B: 7.1%), and vomiting (Part A: 4.2%; Part B: 7.1%). Overall, TE-8105 was safe and well tolerated with pharmacokinetics potentially allowing for less frequent SC dosing than currently available GLP-1 receptor agonists.

Full Text

Full text is available at the source.

View Full Text ↗

Funding

Competing interests

TMP was contracted by Immunwork, Inc. as the principal investigator for the study. Y‐SC, JDW, M‐TW, H‐MC, and TWC are employees of Immunwork, Inc. H‐MC, and TWC are employees of T‐E Meds, Inc. W‐SY was contracted by Immunwork, Inc. as the scientific advisor. KJP declares no conflicts of interest.

PubMed

First Human Study of a Long-Lasting GLP-1 Drug in Overweight or Obese Adults Without Type 2 Diabetes

Abstract

Full Text

Funding

Competing interests

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief

Abstract

Full Text

Funding

Competing interests

Related papers

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief